Wolfram Brugger

Summary

Affiliation: Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
Country: Germany

Publications

  1. pmc Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management
    Wolfram Brugger
    Department of Hematology, Oncology, and Palliative Care, Schwarzwald Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen Schwenningen, Germany
    Oncologist 18:954-64. 2013
  2. doi request reprint EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment
    Wolfram Brugger
    Medical Center II, Department of Hematology Oncology, Schwarzwald Baar Clinic, Academic Teaching Hospital University of Freiburg, Villingen Schwenningen, Germany
    Lung Cancer 77:2-8. 2012
  3. doi request reprint Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support
    W Brugger
    Schwarzwald Baar Clinic Villingen Schwenningen, University of Freiburg, Germany
    Crit Rev Oncol Hematol 72:265-9. 2009
  4. ncbi request reprint Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab
    Wolfram Brugger
    Schwarzwald Baar Clinic, Villingen Schwenningen, Teaching Hospital, University of Freiburg, Germany
    Tumori 96:473-7. 2010
  5. doi request reprint Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer
    Wolfram Brugger
    Schwarzwald Baar Klinikum, Academic Teaching Hospital, University of Freiburg, Voehrenbacher Str 23, Villingen Schwenningen, Germany 78050
    J Clin Oncol 29:4113-20. 2011
  6. ncbi request reprint Clearing minimal residual disease with rituximab consolidation therapy
    Wolfram Brugger
    Department of Hematology, Oncology, and Immunology, University of Tubingen, Tubingen, Germany
    Semin Oncol 31:33-7. 2004
  7. doi request reprint Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximab
    Georgios Papakonstantinou
    Medical Center, Department of Hematology Oncology, Schwarzwald Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen Schwenningen, Germany
    Eur J Haematol 84:547-9. 2010
  8. doi request reprint Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor
    Katharina Wagner
    Department of Hematology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Clin Oncol 28:2356-64. 2010
  9. ncbi request reprint Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders
    Katja C Weisel
    Department of Hematology, Oncology and Immunology, University of Tubingen, Medical Center, Otfried Muller Strasse 10, D 72076 Tubingen, Germany
    Hematol J 5:444-6. 2004

Collaborators

Detail Information

Publications9

  1. pmc Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management
    Wolfram Brugger
    Department of Hematology, Oncology, and Palliative Care, Schwarzwald Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen Schwenningen, Germany
    Oncologist 18:954-64. 2013
    ..In addition, this review provides practical advice on how to optimally manage bendamustine therapy in patients with NHL. ..
  2. doi request reprint EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment
    Wolfram Brugger
    Medical Center II, Department of Hematology Oncology, Schwarzwald Baar Clinic, Academic Teaching Hospital University of Freiburg, Villingen Schwenningen, Germany
    Lung Cancer 77:2-8. 2012
    ..g. EGFR and MET) and vertical inhibition by combination of small molecules and antibodies, seem to be more promising and will be the prevailing concepts to overcome secondary EGFR-TKI resistance for the near future...
  3. doi request reprint Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support
    W Brugger
    Schwarzwald Baar Clinic Villingen Schwenningen, University of Freiburg, Germany
    Crit Rev Oncol Hematol 72:265-9. 2009
    ..0 x 10(9)/L versus approximately 25% of those receiving no pegfilgrastim. In conclusion, cycle 1 pegfilgrastim improved recovery from severe neutropenia in elderly breast cancer patients receiving adjuvant FEC100...
  4. ncbi request reprint Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab
    Wolfram Brugger
    Schwarzwald Baar Clinic, Villingen Schwenningen, Teaching Hospital, University of Freiburg, Germany
    Tumori 96:473-7. 2010
    ..There are only limited data on the safety and efficacy of panitumumab in patients who experienced severe infusion reactions during cetuximab antibody therapy...
  5. doi request reprint Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer
    Wolfram Brugger
    Schwarzwald Baar Klinikum, Academic Teaching Hospital, University of Freiburg, Voehrenbacher Str 23, Villingen Schwenningen, Germany 78050
    J Clin Oncol 29:4113-20. 2011
    ..This study included prospective analysis of the prognostic and predictive value of several biomarkers...
  6. ncbi request reprint Clearing minimal residual disease with rituximab consolidation therapy
    Wolfram Brugger
    Department of Hematology, Oncology, and Immunology, University of Tubingen, Tubingen, Germany
    Semin Oncol 31:33-7. 2004
    ..These studies suggest that rituximab may have an important role in improving the outcome of ASCT in patients with follicular or mantle cell lymphoma...
  7. doi request reprint Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximab
    Georgios Papakonstantinou
    Medical Center, Department of Hematology Oncology, Schwarzwald Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen Schwenningen, Germany
    Eur J Haematol 84:547-9. 2010
    ..At a follow-up of 30 months after treatment, the patient is still in continuous complete remission without any further treatment, suggesting that rituximab may induce prolonged remissions and eventually cure in this rare disease...
  8. doi request reprint Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor
    Katharina Wagner
    Department of Hematology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Clin Oncol 28:2356-64. 2010
    ....
  9. ncbi request reprint Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders
    Katja C Weisel
    Department of Hematology, Oncology and Immunology, University of Tubingen, Medical Center, Otfried Muller Strasse 10, D 72076 Tubingen, Germany
    Hematol J 5:444-6. 2004
    ..We describe here a 76-year-old woman with the clinical diagnoses of hemolytic anemia and progressive lethargy where intravascular lymphomatosis turned out as the underlying cause of the disease...